-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Seize the opportunity: Zhuhai's 100-billion-level biopharmaceutical industry cluster blueprint The total output value of the biopharmaceutical industry will reach 26 billion yuan; in 2025, it will reach 45 billion yuan; in 2035, it will reach 120 billion yuan
.
Zhuhai proposes to focus on biomedicine and accelerate the cultivation of five hundred-billion-level emerging industry clusters
.
”
It can be said that the policy outlines the “timetable” and “roadmap” for Zhuhai to expand and strengthen the biomedical industry, which will serve as a basis for Zhuhai The high-quality development of the biopharmaceutical industry has created a good development environment, and has also released to the outside world the firm confidence in Zhuhai to build a 100 billion-level biopharmaceutical industry cluster
.
Active layout: industry famous enterprises have gathered in April MIDC2021 April 9-11, 2021 , sponsored by China National Health Association and China National Health Association Medical Industry Professional Committee, undertaken by Guangzhou Zhenwei Exhibition Co.
, Ltd.
and Zhuhai Huafa Exhibition Co.
, Ltd.
, and Zhuhai Foreign Economic Cooperation Enterprise Association (Zhuhai Jinwan National Foreign Trade Transformation and Upgrading Base (Biological The 4th Medical Industry Innovation and Development Conference (MIDC2021), co-organized by Guangdong Medical Valley, will be held in Zhuhai Convention and Exhibition Center
.
The conference will be in the form of "theme conference + parallel forum + expo".
Industry chain exhibition thinking, dig deep into industry resources, and enhance the value of the conference
.
Build a panoramic display platform for biomedical science and technology innovation, and accelerate the formation of an innovative development model of "world technology + Zhuhai biomedicine + market"
.
It is expected that more than 300 exhibitors will participate in the exhibition.
With an area of 15,000 square meters and more than 15,000 professional visitors, it is the first annual biomedical industry event in the Guangdong-Hong Kong-Macao Greater Bay Area
.
The conference attracted Fuji, Keyence, BGI, Lepu Medical, Zhao Derivatives, Kindly, Xiangxue Pharmaceutical, Hualan Bio, Tigermed, Boji Bio, Hisense Commercial Cold Chain, Tianxiangyuan, Zhao More than 300 listed companies such as derivatives, National Gene Bank, Medicilon, and Fujian Saite made their appearances, focusing on displaying biotechnology, raw material supply, CRO/CMO services, laboratory equipment, drug research and development, medical consumables, medical imaging, Bioengineering technology equipment, production of epidemic prevention products and other new products and technologies
.
FUJIFILM Irvine Scientific (Fujifilm Irvine Scientific): Focus on the innovative R&D and production of cell culture products FUJIFILM Irvine Scientific (Fujifilm Irvine Scientific) is a high-tech company focusing on the innovative R&D and production of cell culture products.
In the fields of industrial cell culture, assisted reproduction, cell therapy and cytogenetics, we continue to provide scientific research, industrial customers and clinicians with high-quality, reliable products and flexible and customized excellent services
.
The company always complies with the strict supervision of ISO and FDA, and has cGMP dry powder medium production facilities in California, USA and Tokyo, Japan at the same time
.
BGI: Gene science and technology for the benefit of mankind BGI adheres to the vision of "gene science and technology for the benefit of mankind", with the starting point of promoting the progress of life science research, the application of life big data and improving the level of medical and health, based on the research results in the field of genetics and accurate detection technology.
The application of people's livelihood and health is committed to accelerating scientific and technological innovation, reducing birth defects, strengthening tumor prevention and control, inhibiting the harm of major diseases to human beings, realizing precise cure of infections, and comprehensively assisting precision medicine
.
The company is headquartered in Shenzhen, China, with branches and medical laboratories in major domestic cities such as Beijing, Tianjin, Wuhan, Shanghai, Guangzhou, Hong Kong, and overseas centers and core laboratories in Europe, America, Asia-Pacific and other regions.
Form a network layout of "covering the whole country and radiating"
.
Lepu Medical: Committed to bringing more mobile medical services to residents, Lepu (Beijing) Medical Equipment Co.
, Ltd.
(“Lepu Medical”, stock code 300003) was founded in 1999 and is the earliest cardiovascular intervention in China.
One of the companies engaged in the R&D and manufacturing of medical devices, it is the National Research Center for Cardiology, Interventional Diagnosis and Treatment Devices and Equipment Engineering Technology Research Center granted by the Ministry of Science and Technology of the People's Republic of China, and one of the first batch of companies listed on the Growth Enterprise Market in 2009.
One of the few companies with strong competition
.
Over the past 20 years, the company has always focused on serving patients with cardiovascular disease, insisted on R&D and innovation, and continued to make breakthroughs in the fields of cardiovascular stents, pacemakers, cardiovascular drugs and medical artificial intelligence.
It has undertaken many major national scientific research projects, including national National Development and Reform Commission High-tech Industrialization Demonstration Project, National Ministry of Science and Technology 863 Plan Development Project, Science and Technology Support Plan Project,
etc.
At present, the company has developed into a medical product industry group of cardiovascular disease implant interventional diagnosis and treatment devices and equipment.
Its business covers four major sectors: medical devices, pharmaceutical products, medical services and new medical formats
.
KEYENCE: Focus on providing added value to customers by combining excellent technology with outstanding technical support As a supplier of microscopy systems and stand-alone imaging systems, KEYENCE continues to promote innovation and development in factory automation
.
KEYENCE has been committed to developing reliable products to meet the needs of customers in various manufacturing industries
.
In addition to innovative products, KEYENCE offers a wide range of services to further assist customers
.
The consultative sales team that has received professional technical training can not only solve difficult customer application problems, but also provide customers with more effective solutions
.
In addition, KEYENCE's fast delivery service can help customers improve their workflow as soon as possible
.
Zhao Derivatives: Committed to bringing more mobile medical services to residents Zhao Derivatives (stock code: 603127) is an early private CRO enterprise engaged in non-clinical drug evaluation in China.
Since its establishment in 1995, it has a professional and technical team of more than 1,500 people.
, with subsidiaries in Beijing, Suzhou, Chongqing, Wuzhou and San Francisco and Boston in the United States
.
Zhaoyan New Drug has established a standard quality management system (CNAS/ILAC-MRA certification), and has GLP qualifications from China's NMPA, US FDA, OECD OECD, South Korea's MFDS, and AAALAC (animal welfare) certification
.
It can provide customers with one-stop drug evaluation services for drug screening, pharmacodynamics research, pharmacokinetics research, safety evaluation, clinical trials, and pharmacovigilance; it can also provide laboratory animals, food animals/veterinary drug evaluation, and pesticide evaluation.
, medical device evaluation and other services
.
Medicilon: Based on vision, focus on innovation in China, and contribute to human health Medicilon (stock code: 688202) was established in 2004 and is headquartered in Shanghai.
It is a domestic one-stop biomedical preclinical comprehensive R&D service CRO, dedicated to To provide multi-faceted preclinical new drug research services for pharmaceutical companies, research institutions and scientific researchers
.
The company has more than 16 years of experience in pharmaceutical R&D outsourcing services, covering the whole process of pre-clinical new drug research.
It is a standard-compliant comprehensive technical service platform integrating toxicological safety evaluation preparation research and new drug registration, and has been recognized by the drug administration department
.
Standing on the node of the construction of the Guangdong-Hong Kong-Macao Greater Bay Area, Zhuhai continues to build a biomedical industry highland with greater efforts, higher standards and more practical measures, promote the high-quality development of Zhuhai's economy, and actively move towards a 100 billion health industry cluster
.
The convening of the 4th Medical Industry Innovation and Development Conference will make full use of Zhuhai's biopharmaceutical industry foundation and the advantages of gathering resources from Hong Kong and Macao, facilitate in-depth cooperation in the field of biopharmaceutical industry between Guangdong and Macao, and build a platform for the upstream and downstream of the biopharmaceutical industry chain
.
For pre-registration and contact information, please click the relevant information below to download
.
Zhuhai proposes to focus on biomedicine and accelerate the cultivation of five hundred-billion-level emerging industry clusters
.
”
It can be said that the policy outlines the “timetable” and “roadmap” for Zhuhai to expand and strengthen the biomedical industry, which will serve as a basis for Zhuhai The high-quality development of the biopharmaceutical industry has created a good development environment, and has also released to the outside world the firm confidence in Zhuhai to build a 100 billion-level biopharmaceutical industry cluster
.
Active layout: industry famous enterprises have gathered in April MIDC2021 April 9-11, 2021 , sponsored by China National Health Association and China National Health Association Medical Industry Professional Committee, undertaken by Guangzhou Zhenwei Exhibition Co.
, Ltd.
and Zhuhai Huafa Exhibition Co.
, Ltd.
, and Zhuhai Foreign Economic Cooperation Enterprise Association (Zhuhai Jinwan National Foreign Trade Transformation and Upgrading Base (Biological The 4th Medical Industry Innovation and Development Conference (MIDC2021), co-organized by Guangdong Medical Valley, will be held in Zhuhai Convention and Exhibition Center
.
The conference will be in the form of "theme conference + parallel forum + expo".
Industry chain exhibition thinking, dig deep into industry resources, and enhance the value of the conference
.
Build a panoramic display platform for biomedical science and technology innovation, and accelerate the formation of an innovative development model of "world technology + Zhuhai biomedicine + market"
.
It is expected that more than 300 exhibitors will participate in the exhibition.
With an area of 15,000 square meters and more than 15,000 professional visitors, it is the first annual biomedical industry event in the Guangdong-Hong Kong-Macao Greater Bay Area
.
The conference attracted Fuji, Keyence, BGI, Lepu Medical, Zhao Derivatives, Kindly, Xiangxue Pharmaceutical, Hualan Bio, Tigermed, Boji Bio, Hisense Commercial Cold Chain, Tianxiangyuan, Zhao More than 300 listed companies such as derivatives, National Gene Bank, Medicilon, and Fujian Saite made their appearances, focusing on displaying biotechnology, raw material supply, CRO/CMO services, laboratory equipment, drug research and development, medical consumables, medical imaging, Bioengineering technology equipment, production of epidemic prevention products and other new products and technologies
.
FUJIFILM Irvine Scientific (Fujifilm Irvine Scientific): Focus on the innovative R&D and production of cell culture products FUJIFILM Irvine Scientific (Fujifilm Irvine Scientific) is a high-tech company focusing on the innovative R&D and production of cell culture products.
In the fields of industrial cell culture, assisted reproduction, cell therapy and cytogenetics, we continue to provide scientific research, industrial customers and clinicians with high-quality, reliable products and flexible and customized excellent services
.
The company always complies with the strict supervision of ISO and FDA, and has cGMP dry powder medium production facilities in California, USA and Tokyo, Japan at the same time
.
BGI: Gene science and technology for the benefit of mankind BGI adheres to the vision of "gene science and technology for the benefit of mankind", with the starting point of promoting the progress of life science research, the application of life big data and improving the level of medical and health, based on the research results in the field of genetics and accurate detection technology.
The application of people's livelihood and health is committed to accelerating scientific and technological innovation, reducing birth defects, strengthening tumor prevention and control, inhibiting the harm of major diseases to human beings, realizing precise cure of infections, and comprehensively assisting precision medicine
.
The company is headquartered in Shenzhen, China, with branches and medical laboratories in major domestic cities such as Beijing, Tianjin, Wuhan, Shanghai, Guangzhou, Hong Kong, and overseas centers and core laboratories in Europe, America, Asia-Pacific and other regions.
Form a network layout of "covering the whole country and radiating"
.
Lepu Medical: Committed to bringing more mobile medical services to residents, Lepu (Beijing) Medical Equipment Co.
, Ltd.
(“Lepu Medical”, stock code 300003) was founded in 1999 and is the earliest cardiovascular intervention in China.
One of the companies engaged in the R&D and manufacturing of medical devices, it is the National Research Center for Cardiology, Interventional Diagnosis and Treatment Devices and Equipment Engineering Technology Research Center granted by the Ministry of Science and Technology of the People's Republic of China, and one of the first batch of companies listed on the Growth Enterprise Market in 2009.
One of the few companies with strong competition
.
Over the past 20 years, the company has always focused on serving patients with cardiovascular disease, insisted on R&D and innovation, and continued to make breakthroughs in the fields of cardiovascular stents, pacemakers, cardiovascular drugs and medical artificial intelligence.
It has undertaken many major national scientific research projects, including national National Development and Reform Commission High-tech Industrialization Demonstration Project, National Ministry of Science and Technology 863 Plan Development Project, Science and Technology Support Plan Project,
etc.
At present, the company has developed into a medical product industry group of cardiovascular disease implant interventional diagnosis and treatment devices and equipment.
Its business covers four major sectors: medical devices, pharmaceutical products, medical services and new medical formats
.
KEYENCE: Focus on providing added value to customers by combining excellent technology with outstanding technical support As a supplier of microscopy systems and stand-alone imaging systems, KEYENCE continues to promote innovation and development in factory automation
.
KEYENCE has been committed to developing reliable products to meet the needs of customers in various manufacturing industries
.
In addition to innovative products, KEYENCE offers a wide range of services to further assist customers
.
The consultative sales team that has received professional technical training can not only solve difficult customer application problems, but also provide customers with more effective solutions
.
In addition, KEYENCE's fast delivery service can help customers improve their workflow as soon as possible
.
Zhao Derivatives: Committed to bringing more mobile medical services to residents Zhao Derivatives (stock code: 603127) is an early private CRO enterprise engaged in non-clinical drug evaluation in China.
Since its establishment in 1995, it has a professional and technical team of more than 1,500 people.
, with subsidiaries in Beijing, Suzhou, Chongqing, Wuzhou and San Francisco and Boston in the United States
.
Zhaoyan New Drug has established a standard quality management system (CNAS/ILAC-MRA certification), and has GLP qualifications from China's NMPA, US FDA, OECD OECD, South Korea's MFDS, and AAALAC (animal welfare) certification
.
It can provide customers with one-stop drug evaluation services for drug screening, pharmacodynamics research, pharmacokinetics research, safety evaluation, clinical trials, and pharmacovigilance; it can also provide laboratory animals, food animals/veterinary drug evaluation, and pesticide evaluation.
, medical device evaluation and other services
.
Medicilon: Based on vision, focus on innovation in China, and contribute to human health Medicilon (stock code: 688202) was established in 2004 and is headquartered in Shanghai.
It is a domestic one-stop biomedical preclinical comprehensive R&D service CRO, dedicated to To provide multi-faceted preclinical new drug research services for pharmaceutical companies, research institutions and scientific researchers
.
The company has more than 16 years of experience in pharmaceutical R&D outsourcing services, covering the whole process of pre-clinical new drug research.
It is a standard-compliant comprehensive technical service platform integrating toxicological safety evaluation preparation research and new drug registration, and has been recognized by the drug administration department
.
Standing on the node of the construction of the Guangdong-Hong Kong-Macao Greater Bay Area, Zhuhai continues to build a biomedical industry highland with greater efforts, higher standards and more practical measures, promote the high-quality development of Zhuhai's economy, and actively move towards a 100 billion health industry cluster
.
The convening of the 4th Medical Industry Innovation and Development Conference will make full use of Zhuhai's biopharmaceutical industry foundation and the advantages of gathering resources from Hong Kong and Macao, facilitate in-depth cooperation in the field of biopharmaceutical industry between Guangdong and Macao, and build a platform for the upstream and downstream of the biopharmaceutical industry chain
.
For pre-registration and contact information, please click the relevant information below to download
